SpyGlass Pharma, Inc., was incorporated on January 7, 2019 under the laws of the State of Delaware. The company, a late-stage biopharmaceutical company, is initiating Phase 3 clinical trials of its lead product, an IOL-mounted, controlled-release, drug delivery system designed to treat glaucoma through delivery of the drug bimatoprost. Its mission is to significantly improve the lives of patients with chronic eye diseases by developing durable drug delivery solutions that give patients and surgeons confidence in long-term disease control and vision protection.
